Fumonisin B 1 (FB 1 ) is a mycotoxin produced by Fusarium spp. moulds that contaminate crop, predominantly maize, all around the world. More than 15 types of fumonisins have been indentifi ed so far, but FB 1 is the most abundant and toxicologically the most signifi cant one. FB 1 has a wide range of toxic effects, depending on animal species. In horses FB 1 causes equine leukoencephalomalacia (ELEM), in pigs pulmonary oedema and in experimental rodents nephrotoxicity and hepatotoxicity. In humans exposure to FB 1 is linked with higher incidence of primary liver cancer and oesophageal cancer, which are frequent in certain regions of the world (such as Transkei region in South Africa) where maize is staple food. The occurrence of neural tube defect in children in some countries of Central America (such as Mexico and Honduras) is connected with the consumption of FB 1 -contaminated maize-based food. However, possible involvement of FB 1 in the development of human diseases is not clear. Nevertheless, the International Agency for Research on Cancer (IARC) has classifi ed FB 1 as a possible carcinogen to humans (group 2B). FB 1 is a causative agent of ELEM, a brain disorder in equines, indicating that brain is a target organ of FB 1 toxicity. Several studies on experimental animals or on cell cultures of neural origin have established that FB 1 has a neurodegenerative potential, although the mechanism of its neurotoxicity is still vague. The aim of this article is to give an overview of available literature on FB 1 neurotoxicity and involved mechanisms, and to offer a new perspective for future studies.
Fumonisins are a group of mycotoxins produced by Fusarium spp. moulds, mainly by Fusarium verticilloides (formerly F. moniliforme) mould (1, 2) . Fumonisins were first isolated and chemically characterised by South African scientists in 1988 (3) . More than 15 types of fumonisins have been identifi ed so far (Figure 1 ). The most abundant and the most toxic fumonisin is fumonisin B 1 (FB 1 ) (1). As contaminants, fumonisins are found throughout the world in various crops, but predominately in maize (reviewed by Sorriano and Dragacci, ref. 4) .
Consumption of FB 1 -contaminated feed causes p u l m o n a r y o e d e m a i n p i g s a n d e q u i n e leukoencephalomalacia (ELEM) in horses (1) . To experimental animals (rats and mice) FB 1 is nephrotoxic and hepatotoxic. Chronic dietary exposure of rats and mice of both sexes to FB 1 resulted in signifi cant increases in kidney tumours in male BD IX rats and liver tumours in male F344 rats and female B6C3F 1 mice, which suggests that FB 1 toxicity is sex-, strain-, and species-dependent (5, 6) . As for FB 1 pharmacokinetics, it is poorly absorbed from the gastrointestinal tract, rapidly eliminated from plasma, and not extensively accumulated in tissue, although low amounts are found in the liver and kidney (for review see ref.
2). The effect of FB 1 on human health is uncertain. There is a record of only one outbreak of foodborne disease connected with exposure to FB 1 (7) . In 1995, due to unseasonal rains in the Deccan plateau in India, consumption of damaged maize and sorghum led to an outbreak characterised by abdominal pain, borborygmi, and diarrhoea. A rapid epidemiological survey of food samples collected from the affected households revealed higher levels of Fusarium spp. and FB 1 compared to food samples collected from unaffected households. Additionally, diarrhoea was reproduced in one-day-old cockerels fed with contaminated grains from the affected households. In certain regions of the world such as the Transkei region in South Africa and Linxian region in China, where maize is staple food, higher incidence of oesophageal cancer and primary liver cancer were connected with dietary exposure to FB 1 (1) . However, epidemiological data are still lacking and a direct causal role for this toxin in the aetiology of such tumours has not been established (1, 8) . FB 1 has also been implicated in the aetiology of neural tube defect (NTD) in parts of Texas, Mexico, Guatemala, and South Africa. Studies on mouse embryos in culture and on pregnant mice have provided evidence that FB 1 has the potential to produce embryotoxicity and NTD (9, 10) . In a case-control study conducted on Mexican American women in Texas, maternal exposure to FB 1 (assessed as level of FB 1 in tortillas consumed by mothers and level of biomarker of FB 1 exposure in maternal serum) was associated with increased incidence of NTD in children (11) . This established an association between exposure to FB 1 -contaminated food and NTD, but further investigations are required to establish the connection between FB 1 and NTD (12, 13) . On the basis of the available toxicological evidence, International Agency for Research on Cancer (IARC) has classifi ed FB 1 in group 2B as a possible carcinogen to humans (14) .
Although FB 1 has a wide range of biological effects, brain is undoubtedly a target organ of FB 1 toxicity. For the last three decades, extensive studies on FB 1 toxicity have been conducted, but only a few have looked into its neurodegenerative potential. Moreover, the underlying mechanism of FB 1 toxicity as well as neurotoxicity is still not known. Therefore, the aim of this article is to give an overview of available literature on the neurotoxic potential and studied mechanisms of FB 1 neurotoxicity, and offer a new perspective for future studies.
NEUROTOXIC POTENTIAL OF FB 1
ELEM is a neurotoxic syndrome with high mortality in equines, associated with FB 1 -contaminated feed (15, 16 , for recent review see ref 2). The disease is characterised by a sudden development of nervous signs such as aimless circling, head pressing, paresis, ataxia, blindness, and depression, and concurrently by changes in the liver (15) . The primary pathological feature of ELEM is focal necrosis of cerebral white (16) . As the level of FB 1 contamination required to induce ELEM is low, it is not surprising that this equine neurotoxic disease has been reported worldwide (2) . However, as only several horses on the same farm are usually affected by ELEM, this suggests that in addition to the level of dietary contamination, other factors are involved in its development such as length of exposure, individual susceptibility, and previous exposure to FB 1 (2) .
Experiments on animals
Only a few animal studies have reported FB 1 effects on the central nervous system (CNS), mainly because there are no suitable laboratory animal models to study ELEM (21) . Rabbits gavaged with purifi ed FB 1 (1.75 mg kg -1 b.w. for 9 and 13 days) showed CNS changes similar to ELEM, such as focal small haemorrhages in cerebral white matter (22) . A hyperaemia was observed in the brain of adult female Fischer rats, but these animals were fed with FB 1 (1 mg kg -1 diet, for 17 days) together with Ustilago maydis, a facultative biotrophic basidiomycete, another well-known contaminant of maize (23) . In a study on developing rats, multiple subcutaneous dosing with FB 1 (0.4 mg kg -1 or 0.8 mg kg -1 b.w. a day, from postnatal day 3 to 12) signifi cantly reduced body and brain weights and caused hypomyelination (24) . The same group of authors demonstrated that FB 1 crosses the blood-brain barrier in developing rats after a single subcutaneous FB 1 dose (8 mg kg -1 b.w.) (25) . However, the level of FB 1 in the brain was low, and at low-dose treatment (0.8 mg kg -1 b.w.) no FB 1 was found in the brain. Authors suggested that this was probably due to low lipid solubility and a large molecular weight of FB 1 . In a study of FB 1 toxicity in fi sh brain (26) , one-year-old carps (Cyprinus carpio L.) were receiving FB 1 in feed (100 mg kg -1 diet or 10 mg kg -1 diet) for 42 days. Both FB 1 -exposed groups showed slower body-weight gain and histopathological changes such as brain oedema, increase in the number of degenerative cells, and accumulation of infl ammatory cells. FB 1 was again found to cross the blood-brain barrier in young carp, confi rming the fi ndings of Kwon et al. (25) .
Experiments on cell cultures
Several in vitro studies on cell cultures of CNS origin demonstrated that FB 1 caused changes such as disruption of axonal outgrow and myelination, and these changes were observed before FB 1 induced cell death. However, it is not clear which cell types in the brain tissue are more sensitive to FB 1 and are the likely target for the initial degenerative effect of FB 1 .
In a study of Harel and Futerman (27) (21) . On the another hand, incubation with 50 μmol L -1 for 6 days resulted in no change in the viability of rat primary astrocytes, but treatment in that study started after two weeks in vitro, when astrocytes were well mature and differentiated (30) . Therefore, it is hard to compare in vitro results of FB 1 cytotoxicity. Using several parameters, Stockmann-Juvala et al. (36) 
FB 1 EFFECT ON NEUROTRANSMITTERS
Changes in neurotransmitters and their metabolites can be used as an index of toxic effects of chemicals in the CNS (37, 38) . Several studies have looked into the effects of FB 1 on brain neurochemistry and imbalance in neurotransmitters and their metabolism (39-41). Porter et al. (39) studied the levels of several neurotransmitters and their metabolites in whole brain of rats fed F. verticilloides-contaminated corn (ELEMassociated) and rodent chow supplemented with F. verticilloides and established an increase in 5-hydroxyindoleacetic acid (5-HIAA), a major metabolite of serotonin, and subsequently an increase in 5-HIAA to serotonin ratio. As the level of serotonin, a 5-HIAA precursor, did not change, the authors concluded that fumonisins may have affected either serotonin metabolism or 5-HIAA elimination from rat brain. However, another study by the same authors in which rats were fed with purifi ed FB 1 (15, 50 and 150) mg kg -1 in feed for 4 weeks, showed no change in brain serotonin metabolism, but a decrease in norepinephrine to dopamine ratio. This suggests that FB 1 disturbs brain norepinephrine and/or dopamine homeostasis (40) . Since the rats in the first study received F. verticilloides-contaminated diet and in the second study purified FB 1 , the authors contributed the discrepancy to the effects of other mycotoxins produced by Fusarium spp. Imbalance in neurotransmitter metabolism was confirmed by Tsunoda et al. (41) in a study on mice treated with purifi ed FB 1 . Subcutaneous FB 1 treatment (6.75 mg kg -1 b.w.) in the cervical region for 5 days signifi cantly increased homovanillic acid, a dopamine metabolite, in most brain regions, as well as neurotransmitter metabolite to neurotransmitter ratio (such as homovanillic acid to dopamine and 5-HIAA to serotonin). Tsunoda et al. explain this accumulation of neurotransmitter metabolites after FB 1 treatment with increased neuronal activity or changes in their efflux from cells due to disrupted membrane transport.
Recently, Gbore (42) studied the catalytic activity of acetylcholinesterase (AChE) in several brain regions of weanling pigs fed with FB 1 (0.2 mg kg -1 to 15.0 mg kg -1 diet) for 6 months. AChE activities in the pons, amygdala, hypothalamus, and medulla oblongata declined significantly with increase in dietary FB 1 concentrations, indicating that FB 1 has a potential to change brain neurochemistry in growing pigs. In an earlier study, Pepeljnjak et al. (23) found no signifi cant changes in AChE activity in the brain of adult female Fischer rats fed with FB 1 (1 mg kg -1 diet) and Ustilago maydis contaminated diet for 17 days, even though the catalytic activity was lower than in control animals. This result should be taken with reserve, since animals were not receiving FB 1 alone.
Although the fi ndings on neurotransmitters are not consistent, FB 1 was able to disturb brain neurochemistry in rats, mice, and pigs, indicating that further studies are needed. All the more so, as Banczerowski-Pelyhe et al. (43) have shown that FB 1 modifies signal transmission in the brain. Electrophysiological recordings in vivo and in cortex slices in vitro showed changes in excitability in the neocortex of rats fed with FB 1 (calculated to be 30 mg kg -1 b.w.) for 5 days and their greater susceptibility to seizure. The authors concluded that this type of neuronal stress may stem from altered membrane processes and neurotransmitter level imbalance that could even be related to systemic toxic effects of FB 1 .
MECHANISM OF FB 1 NEUROTOXICITY

Impairment of sphingolipid metabolism
The chemical structure of FB 1 is similar to sphingosine and sphinganine, the backbones of sphingolipids (SLs), a class of complex lipids ( Figure  2 ). As a result of this similarity, FB 1 competitively inhibits a key enzyme in SL metabolism ceramide s y n t h a s e [ s p h i n g o s i n e ( s p h i n g a n i n e ) Nacetyltransferase] (44, 45) . Inhibition of ceramide synthase results in a decrease of de novo biosynthesis of ceramide and complex SLs and in blocking the reuse of sphingosine liberated during SL turnover ( Figure 3 ). The blocking of these pathways by FB 1
Figure 2 Structural formula of sphingolipids and sphingoid bases. A) General formula -sphingoid base sphingosine is the backbone of sphingolipids to which fatty acids tail (framed) is linked. Specifi c sphingolipid molecule depends on the substituent (R) linked to sphingosine [-such as hydrogen (ceramide), phosphocholine (sphingomyelin), and sugar (glycosphingolipid)]. B) structural formula of sphingosine and C) of sphinganine.
leads to an increase in free sphinganine and to a lesser extent in sphingosine, and consequently to increase in sphingoid base 1-phosphate metabolites, while ceramide and complex SL levels drop (2, 45) . Increased levels of sphinganine in blood, plasma, and tissues and the accompanying increase in sphinganine to sphingosine ratio can be used as biomarkers of exposure to FB 1 , but only in experimental conditions (2, 46) . The use of sphinganine to sphingosine ratio as a biomarker of exposure in epidemiological studies is not reliable (47) , as the human population is exposed to much lower levels of FB 1 than experimental animals and since changes in sphingoid base concentrations are reversible (2, 47) . Animal studies and studies of neuronal and glial cells have confi rmed that FB 1 treatment alters SL metabolism in the CNS. In developing rats treated with multiple subcutaneous doses of FB 1 (0.4 mg kg -1 or 0.8 mg kg -1 b.w. per day) from postnatal day 3 to 12, brain sphinganine and sphinganine to sphingosine ratio signifi cantly increased with the highest dose (24) . In another study (25) , the same group of authors showed that brain SL metabolism disturbed by a single subcutaneous dose of FB 1 (8 mg kg -1 b.w.) in developing rats was a consequence of direct action of ) increased sphinganine level and sphinganine to sphingosine ratio after 5 days of treatment and decreased sphingosine level after 10 days (29) . In a study by Osuchowski and Sharma (21), FB 1 (50 μmol L -1 ) increased sphinganine and decreased sphingosine level in murine BV-2 microglial and murine N2A neuroblastoma after 4 days of treatment, and in primary astrocytes and primary cortical neurons after 8 days.
Disturbed SL metabolism is an immediate event after FB 1 treatment that appears before any toxic effects of FB 1 (44, 45) . This suggests that disturbed SL metabolism is behind FB 1 toxicity (21, 29, 49) . However, the mechanism by which changes in SL biosynthesis induce cell death is not clear. Since SLs are major structural components of cell membranes, one of the certain consequences of disturbed SL metabolism is a change in cellular membrane function. Several studies on FB 1 -treated cells of CNS origin attributed the disruption of neuronal growth, hypomyelination, and folic acid transport to altered SL metabolism (24, 27, 50) .
In a study by Harel and Futerman (27) ) for 24 h, however, reversed the effect of FB 1 on axonal outgrowth. This suggests that SLs, more specifi cally ceramide, are important for normal neuron development. Another study by the same group has confi rmed that SLs play an important role in the formation and stabilisation of axonal branches (48) . In that study, cultured rat hippocampal neurons incubated with FB 1 (10 μmol L -1 ) for 66 h had a shorter axonal plexus and less axonal branches, which correlated with a decrease in complex SLs ganglioside, sphingomyelin, and glucosylceramid.
In a study by Kwon et increased sphinganine level and sphinagnine to sphingosine ratio in the CNS were accompanied by hypomyelination. In addition to lower myelin deposition, the authors observed a decrease in the activity of 2',3'-cyclic nucleotide 3'-phosphohydrolase (CNP), a myelin-associated enzyme. Similarly, a tenday FB 1 treatment (3 μmol L -1 to 40 μmol L -1 ) impaired myelin formation and deposition, and delayed oligodendrocyte maturation in aggregating brain cell cultures prepared from foetal rat telencephalon (28) . However, CNP did not change in that study.
Altered complex SL metabolism by FB 1 can disrupt cell membrane integrity, affecting receptor function such as folate receptor, thereby affecting the transport of folic acid (50, 51) . In a study by Stevens and Tang (50) on Caco-2 cells, FB 1 depleted complex SLs, which brought cellular uptake of folate by its receptor to a complete halt. This clearly shows that FB 1 treatment disrupts folate receptor function. It is well known that folate defi ciency is a risk factor for NTD. In a study of Sadler et al. (51) reduced folate uptake by FB 1 was connected to embryotoxicity and to NTD. Whole mouse embryo cultures treated with FB 1 (50 μmol L -1 for 2 h) showed a high incidence of NTDs (66.7 %), but when treated with a combination of FB 1 and folic acid (1 mmol L -1 ) this incidence dropped to 34.3 %. In a long-term experiment within the same study, mouse embryos treated with 1 μmol L -1 to 100 μmol L -1 FB 1 for 26 h showed a dosedependent increase in NTD together with an increase in sphinganine levels and the sphinganine to sphingosine ratio, but this increase in biomarkers was not dose-dependent. Folic acid (1 mmol L -1 ) decreased NTD incidence, but did not reduce the inhibition of SL synthesis.
SLs and their metabolites are important messengers involved in signal transduction, leading to either cell survival or cell death (45, 52) . Findings about FB 1 effects on the cell cycle and cell death are not consistent. Some report that FB 1 stimulates cell growth and inhibits apoptosis (29, 53) , and some claim the opposite (21, 30) . After FB 1 treatment, some observed apoptosis as well as necrosis.
Kwon et al. (29) reported a proliferative effect of FB 1 in rat primary astrocytes and oligodendrocytes. An increase in the number of process-bearing cells after FB 1 treatment (0.5 μmol L -1 to 75 μmol L -1 , for 5 or 10 days) was noted, which suggests that FB 1 may modify the proliferation or differentiation of glial cells (29) . On the other hand, Galvano et al. (30) Of all cell types tested (murine BV-2 microglial, mouse primary astrocytes, mouse primary cortical neurons, and murine N2A neuroblastoma), only murine BV-2 microglial cells showed a dose-dependent decline in proliferation after FB 1 treatment. As FB 1 treatment did not alter the ratio of microglia cells in different phases of the cell cycle, the authors concluded that the observed anti-proliferative effect of FB 1 did not relay on the cell cycle. In the same study, FB 1 (50 μmol L -1 after 6 h and 24 h) suppressed TNFα and IL-1β signalling in microglial and primary astrocytes. Additionally, the authors observed necrosis but not apoptosis in murine BV-2 microglial cells and primary astrocytes and linked the absence of apoptosis to the down-regulation of TNFα and IL-1β. Moreover, the authors suggested that pro-apoptotic signalling is dysfunctional in cell lines less sensitive to FB 1 and that FB 1 -induced cell loss is primarily caused by necrosis. In contrast, Mobio et al. (31) showed that FB 1 modifi ed the distribution of rat C6 glioblastoma cells in different cell cycle phases. FB 1 treatment (3 μmol L -1 to 18 μmol L -1 for 24 h) increased the number of cells in G2/M phase and decreased the number of cells in S phase. Arrest in G2/M phase was not dose-related but was induced by a concentration of FB 1 as low as 3 μmol L -1 that was not cytotoxic to C6 glioblastoma cells. Since in this study FB 1 also induced hypermethylation of the DNA, the authors connected cell cycle arrest after FB 1 treatment with the genotoxic potential of FB 1 . In the next study by the same authors (53) on C6 glioblastoma cells treated with FB 1 (3 μmol L -1 to 27 μmol L -1 for 24 h) DNA fragmentation parameters such as DNA laddering, DNA damage verifi ed by the comet assay, and evident apoptotic bodies (revealed by chromatin staining with acridine orange and ethidium bromide) pointed to the pro-apoptotic effect of FB 1 . To check the involvement of p53 gene in FB 1 -induced apoptosis and cell cycle, the same group of authors used two cell types, rat C6 glioblastoma with normal p53 status, and p53-null MEF mouse embryonic fi broblasts (32) . FB 1 treatment (3 μmol L -1 to 36 μmol L -1 for 24 h, 48 h, and 72 h) induced DNA fragmentation in both cell types. However, the number of cells in different phases and increased number of apoptotic bodies were evident only in C6 glioblastoma cells, and no change in the number of cells in different phases and apoptosis were noted in p53-null MEF cells. Therefore, the results of this study indicate that FB 1 -induced DNA damage (observed in both cell types) in cells that lack the p53 function is carried over to the next cell generation, and, as authors concluded, loss of p53 tumour suppressor gene could be responsible for FB 1 -induced tumour promotion. In a study of Stockman-Juvala et al. (36) four different cell types were used, mouse GT1-7 hypothalamic, rat C6 glioblastoma, human U-118MG glioblastoma, and human SH-SY5Y neuroblastoma and were treated with 0.1 μmol L -1 to 100 μmol L -1 FB 1 for 24 h to 144 h. DNA fragmentation was observed in all cells, and increased caspase-3 activity was noted in all cells, except human SH-SY5Y neuroblastoma. However, the expression of p53 and its target proteins from the pro-or anti-apoptotic Bcl-2 family were not affected even with the highest concentration and prolonged exposure, indicating that the p53 dependent mitochondrial Bcl-2 pathway is not important for FB 1 -induced apoptosis in these cells. Loss of viability observed in this study suggests, according to the authors, that FB 1 toxicity involves both apoptosis and necrosis.
The discrepancies between these studies may be owed to different effects of various SL products accumulating after ceramide synthase inhibition by FB 1 . For example, free sphingoid bases, sphinganine and sphingosine, as well as ceramide exert proapoptotic, cytotoxic, and growth inhibitory effects, while sphingoid 1-phosphate metabolites inhibit apoptosis, and promote mitosis and regeneration. Keeping that in mind, the ability of FB 1 to block cell cycle and induce apoptosis depends on various parameters such as cell type, toxin concentrations, and exposure time. As suggested by Desai et al. (52) , it is possible that toxicity occurs in cells that accumulate sphinganine (and sphingosine), and mitogenesis in cells that accumulate sphingoid 1-phosphates. Numerous regulatory pathways involving SLs have been identifi ed that can infl uence apoptotic processes. Control of apoptosis is a complex, non-linear process that is cell-specifi c and dependent on a variety of feedback mechanisms. Thus, as observed by StockmanJuvala et al. (36) , it could be that in different cell lines, different signalling pathways may be involved in the effects of FB 1 .
A recent study by Myburg et al. (54) , where human SNO oesophageal carcinoma cells were treated with FB 1 (1 μmol L -1 to 32 μmol L -1 for 24 h), confi rmed that FB 1 induced cell death by apoptosis and necrosis. Moreover, it pointed to the importance of FB 1 concentration applied. At lower FB 1 concentrations (4 μmol L -1 and 8 μmol L -1 ), morphological changes were observed such as blebbing or vesiculation of the plasma membrane and smaller membrane-bound apoptotic bodies, and the treated cells broke up into smaller bodies with no swelling. Swelling as an indicator of necrosis appeared at higher concentrations (16 μmol L -1 and above). The authors concluded that apoptosis was the likely mechanism of cell death at lower concentrations, whereas necrosis was the mechanism of death at higher concentrations of FB 1 .
However, it is important to emphasise that regardless of how the cell dies (by apoptosis or necrosis), loss of cells initiates compensatory mitosis, and increased proliferation stimulates DNA replication that can lead to cancer development.
Induction of oxidative stress
Yin et al. (55) investigated FB 1 -induced lipid peroxidation and oxidative stress. Treatment of egg yolk phosphatidylcholine (EYPC) bilayers with FB 1 (1 mmol L -1 to 10 mmol L -1 ) increased oxidation, promoted free radical intermediate production, and accelerated chain reactions associated with lipid peroxidation. The authors suggested that FB 1 induced oxidative stress and cell damage through enhanced oxygen transport in cell membranes, which in turn increased membrane permeability. Lipid peroxidation was confi rmed as a mechanism of FB 1 toxicity in a study of Abel and Gelderblom (56) . They observed higher lipid peroxidation in the liver of rats fed with FB 1 (10 mg kg -1 to 500 mg kg -1 diet for 21 days). In primary hepatocytes, treatment with FB 1 (75 μmol L -1 to 500 μmol L -1 for 44 h) increased the level of lipid peroxidation in a dose-dependent manner and was associated with an increase in cytotoxicity. Combined treatment of primary hepatocytes with FB 1 (75 μmol L -1 to 250 μmol L -1 ) and vitamin E (10 μmol L -1 ) for 44 h prevented FB 1 -induced lipid peroxidation, but vitamin E could not completely prevent FB 1 -induced cytotoxicity. The authors concluded that lipid peroxidation was not solely responsible for the cytotoxic effects of FB 1 and played a secondary role as a result of cell injury.
Several studies investigated lipid peroxidation and oxidative stress as the mechanism of FB 1 -induced cell death in cells of CNS origin (30-34, 53) . However, the results of these studies are somehow inconclusive. ). This study suggests that lipid peroxidation is involved in FB 1 cytotoxicity. The same group confi rmed this observation in their subsequent study (32) . In rat C6 glioblastoma and p53 null mouse MEF embryonic fi broblasts, FB 1 (3 μmol L -1 to 36 μmol L -1 for 24 h) induced lipid peroxidation that was prevented by pre-incubation of cells with vitamin E (25 μmol L -1 for 24 h). Furthermore, in both cell lines the authors observed a dose-related increase in 8-oxodG, a marker of oxidative DNA damage. In another study on rat C6 glioblastoma cells by these authors (53) , DNA laddering, DNA fragmentation, and apoptotic bodies indicated that FB 1 treatment (3 μmol L -1 to 27 μmol L -1 for 24 h) stimulated the apoptotic type of cell death. Effects such as DNA fragmentation and apoptotic bodies were prevented by pre-incubation of the cells with vitamin E (25 μmol L -1 for 24 h), which clearly implicates oxidative stress in FB 1 -induced apoptosis. StockmanJuvala et al. (34) confi rmed that oxidative stress played a role in FB 1 neurotoxicity. In human rat C6 glioblastoma and mouse GT1-7 hypothalamic cells FB 1 (in the dose range of 0.1 μmol L -1 to 100 μmol L -1 and exposure time from 48 h to 144 h) increased reactive oxygen species (ROS) and lipid peroxidation, and decreased glutathione levels. These effects were not dose-dependent and were in some instances observed only after treatment with the highest dose and prolonged exposure. Interestingly, in human SH-SY5Y neuroblastoma FB 1 did not increase ROS. In a study that followed (33) , this group of scientists established higher ROS production and lipid peroxidation, and lower glutathione levels in human U-118MG glioblastoma cells after treatment with 0.1 μmol L -1 to 100 μmol L -1 FB 1 for 24 h to 144 h. They also observed DNA laddering and higher caspase-3 activity and concluded, similarly to Mobio et al. (32) , that oxidative stress may be involved in FB 1 -induced apoptosis. Moreover, they suggested a possible sequence of events, as follows: activation of caspase-3 (that was observed at the earliest time point) increases ROS production leading to lipid peroxidation and reduction of intracellular glutathione level, and finally to DNA fragmentation and cell death. In contrast, Galvano et al. (30) did not fi nd any change in ROS production, even though they treated primary cultures of rat astrocytes with FB 1 doses as high as 50 μmol L -1 for as long as six days. They however did fi nd increased DNA damage, caspase-3 activity, and expression of HSP70. The authors concluded that FB 1 fi rst modulates the expression of some genes, rather than activate the pathways involving ROS production.
In our recent study (35) , FB 1 did increase ROS production in primary rat astrocytes and human SH-SY5Y neuroblastoma cells, but the effect was not dose-dependent. Using live imaging and specific inhibitors of ROS sources within the cell, we established that the source of cytosolic ROS after FB 1 -treatment is impaired mitochondrial function. Treatment of astrocytes with FB 1 did not alter the level of lipid peroxidation. Glutathione increased dosedependently, clearly indicating that oxidative stress is not involved in FB 1 toxicity. Moreover, these data suggest that cells responded to FB 1 -increased ROS production by increasing glutathione synthesis to protect themselves from further damage, including lipid peroxidation. Our results support the opinion of other authors (30, 56, 57) that ROS over-production is rather a consequence than a mechanism of FB 1 toxicity. Dragan et al. (45) noted that the chemical structure of FB 1 does not imply pro-oxidant activity and concluded that cellular oxidative damage may be due to toxicity rather than a direct cellular effect of FB 1 . It could be, as Abel and Geldreblom (56) suggested, that FB 1 makes cells more susceptible to lipid peroxidation and cellular damage by disturbing SL metabolism. Nevertheless, these authors continue, oxidative stress may mediate FB 1 carcinogenesis (56). Ongoing cell death, continued production of ROS, and compensatory cellular proliferation, may all favour cancer development.
Recent studies of the mechanisms of FB 1 neurotoxicity
It has already been established that due to its specifi c chemical structure FB 1 targets membranes (55, 56) , but whether it can enter the cell remains unclear. Myburg et al. (54) have shown that FB 1 can actually enter human SNO oesophageal carcinoma cells. In that study, ultrastructural changes were monitored with transmission electron microscopy, and FB 1 detected within the cells with an imunocytochemical method. Transmission electron microscopy revealed enlargement of the nucleus, microsegregation of the nucleolus, signs of membrane damage, and elongated and/or swollen mitochondria. FB 1 was detected in the cytoplasm, nuclei, and mitochondria. Interestingly, it was also detected, to a limited extent, in the mitochondria with no apparent structural changes. As FB 1 is a large and highly polar molecule, it cannot freely permeate membranes. Therefore, the authors suggested that FB 1 may be using the trans-membrane transport system to cross the membrane, probably by mimicking a sphingolipid-type membrane-binding agent. Once in the cell, FB 1 can exert its toxicity by binding to cellular macromolecules or membrane components of the affected organelles. And indeed, in our study (35) we showed that once FB 1 enters the cell, it targets mitochondria and inhibits complex I of the mitochondrial electron transport chain, which lowers the rate of mitochondrial and cellular respiration. In that study FB 1 depolarised the mitochondrial membrane in a dose-dependent manner and was able to increase cytosolic calcium signal [induced by adenosine-5'-triphosphate (ATP)], which suggests that mitochondrial dysfunction caused by FB 1 makes cells vulnerable to physiological calcium signalling. Using cyclosporine A, an inhibitor of mitochondrial membrane permeability, we showed that the opening of membrane transition pores is not involved in cell death induced by FB 1 . This observation is in line with Stockman-Juvala et al. (36) , who observed that the Bcl-2 pathway is not important for FB 1 -induced apoptosis. Taken together, our results suggest that by inhibiting complex I of the mitochondrial electron transport chain FB 1 inhibits cell respiration and lowers mitochondrial membrane potential, which leads to over-production of ROS in mitochondria and to deregulation of calcium signalling (as outlined in Figure 4 ). Eventually, this can lead to cell death.
In our recent study on primary rat neuronal cultures (58), we confi rmed that mitochondrial dysfunction and calcium signalling deregulation are behind FB 1 cytotoxicity. We used three well-established models: 1) the physiological model that involved treatment of neurons with 5 μmol L -1 of glutamate to induce physiological calcium signalling; 2) the glutamate excitotoxicity model (as seen in stroke) induced by treatment of neurons with 100 μmol L -1 of glutamate, which brings calcium signalling to a higher plateau; and 3) the low magnesium model of epilepsy characterised by repetitive calcium oscillations. In all three models, FB 1 increased or changed the shape of calcium signal and simultaneously depolarised mitochondrial membrane. CONCLUSION FB 1 is a neurodegenerative mycotoxin, and ingestion of FB 1 -contaminated food has been associated with a brain disorder in horses, ELEM. However, the mechanism of FB 1 neurotoxicity is still not known. Due to the structural similarity of FB 1 to sphingoid bases, the backbones of SLs, FB 1 inhibits SL metabolism. SLs are important constituents of cell membranes, and by impairing SL metabolism, FB 1 alters membrane functions. One affected function is the folate receptor function, and the effect may be inhibition of folate intake and possibly NTD. SLs are also engaged in signal transduction, and FB 1 may interfere with cell signalling pathways. Experimental evidence suggests that FB 1 has different effects on cell 
